Dmitry Balyasny’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.74M | Sell |
152,280
-239,764
| -61% | -$4.53M | ﹤0.01% | 1662 |
|
|
2026
Q1 | $8.53M | Buy |
392,044
+300,425
| +328% | +$5.81M | 0.01% | 1107 |
|
|
2025
Q4 | $1.97M | Buy |
91,619
+38,135
| +71% | +$804K | ﹤0.01% | 1875 |
|
|
2025
Q3 | $1.03M | Sell |
53,484
-391,244
| -88% | -$6.97M | ﹤0.01% | 2103 |
|
|
2025
Q2 | $7.6M | Buy |
+444,728
| New | +$19M | 0.01% | 1094 |
|
|
2025
Q1 | – | Sell |
-165,973
| Closed | -$17.5M | – | 3255 |
|
|
2024
Q4 | $20.2M | Sell |
165,973
-158,359
| -49% | -$19.4M | 0.03% | 666 |
|
|
2024
Q3 | $40.5M | Sell |
324,332
-208,586
| -39% | -$28.8M | 0.07% | 382 |
|
|
2024
Q2 | $84.2M | Buy |
532,918
+23,713
| +5% | +$3.05M | 0.15% | 163 |
|
|
2024
Q1 | $65.9M | Buy |
509,205
+10,376
| +2% | +$1.27M | 0.12% | 222 |
|
|
2023
Q4 | $48.1M | Buy |
498,829
+278,404
| +126% | +$26.7M | 0.09% | 279 |
|
|
2023
Q3 | $26.7M | Buy |
+220,425
| New | +$24.9M | 0.05% | 475 |
|
|
2023
Q2 | – | Sell |
-61,077
| Closed | -$7.88M | – | 2764 |
|
|
2023
Q1 | $8.42M | Buy |
+61,077
| New | +$7.92M | 0.02% | 844 |
|
|
2022
Q4 | – | Sell |
-368,915
| Closed | -$42.8M | – | 3212 |
|
|
2022
Q3 | $40.8M | Buy |
368,915
+353,814
| +2,343% | +$35.7M | 0.13% | 199 |
|
|
2022
Q2 | $1.13M | Sell |
15,101
-198,530
| -93% | -$14.6M | ﹤0.01% | 1696 |
|
|
2022
Q1 | $16.7M | Buy |
213,631
+107,703
| +102% | +$8.25M | 0.05% | 493 |
|
|
2021
Q4 | $9.54M | Sell |
105,928
-137,308
| -56% | -$11.7M | 0.03% | 646 |
|
|
2021
Q3 | $22.5M | Buy |
243,236
+80,847
| +50% | +$6.23M | 0.09% | 305 |
|
|
2021
Q2 | $12.6M | Buy |
162,389
+124,482
| +328% | +$9.44M | 0.06% | 429 |
|
|
2021
Q1 | $2.83M | Sell |
37,907
-49,702
| -57% | -$4.59M | 0.01% | 910 |
|
|
2020
Q4 | $14.9M | Buy |
+87,609
| New | +$13M | 0.08% | 335 |
|
|
2019
Q3 | – | Sell |
-144,256
| Closed | -$21.9M | – | 1560 |
|
|
2019
Q2 | $21.9M | Sell |
144,256
-15,649
| -10% | -$1.9M | 0.14% | 205 |
|
|
2019
Q1 | $19.1M | Buy |
159,905
+54,266
| +51% | +$6.98M | 0.13% | 233 |
|
|
2018
Q4 | $11.5M | Buy |
105,639
+55,463
| +111% | +$6.94M | 0.08% | 324 |
|
|
2018
Q3 | $8.1M | Sell |
50,176
-127,500
| -72% | -$17.4M | 0.04% | 552 |
|
|
2018
Q2 | $23.5M | Sell |
177,676
-242,446
| -58% | -$22.9M | 0.11% | 270 |
|
|
2018
Q1 | $31.1M | Buy |
420,122
+298,926
| +247% | +$19.9M | 0.13% | 219 |
|
|
2017
Q4 | $6.74M | Buy |
121,196
+17,407
| +17% | +$922K | 0.02% | 757 |
|
|
2017
Q3 | $4.71M | Sell |
103,789
-46,144
| -31% | -$1.84M | 0.02% | 739 |
|
|
2017
Q2 | $5.05M | Sell |
149,933
-289,312
| -66% | -$9.42M | 0.02% | 750 |
|
|
2017
Q1 | $13M | Buy |
439,245
+255,602
| +139% | +$7.91M | 0.06% | 403 |
|
|
2016
Q4 | $5.04M | Buy |
183,643
+67,775
| +58% | +$2.72M | 0.03% | 680 |
|
|
2016
Q3 | $7.12M | Buy |
+115,868
| New | +$3.5M | 0.04% | 448 |
|
|
2015
Q2 | – | Sell |
-11,594
| Closed | -$154K | – | 1310 |
|
|
2015
Q1 | $154K | Buy |
+11,594
| New | +$155K | ﹤0.01% | 876 |
|
|
2013
Q3 | – | Sell |
-140,000
| Closed | -$5.33M | – | 701 |
|
|
2013
Q2 | $5.33M | Buy |
+140,000
| New | +$5.01M | 0.09% | 275 |
|
Other funds holding SRPT
EAM
Dmitry Balyasny's SRPT Position: Q2 2026 in Review
Dmitry Balyasny reduced its Sarepta Therapeutics (SRPT) stake by 61% in Q2 2026, selling an estimated $4.53M and leaving 152,280 shares worth $2.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1662.
Dmitry Balyasny first reported a position in SRPT in Q2 2013 and has held it in 34 quarters since. The position peaked at $84.2M in Q2 2024. 320 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Dmitry Balyasny held 152,280 shares of Sarepta Therapeutics worth $2.74M as of Q2 2026.
- Dmitry Balyasny sold 239,764 Sarepta Therapeutics shares in Q2 2026, an estimated $4.53M.
- Sarepta Therapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1662 holding.
- Dmitry Balyasny first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 34 quarters since.
- Dmitry Balyasny's Sarepta Therapeutics position peaked at $84.2M in Q2 2024.
- 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.